Combinatorial nanomedicines for colon cancer therapy

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 8, Issue 1, 2016, Pages 151-159

  Anitha, A ^a   Maya, S ^a   Sivaram, Amal J ^a   Mony, U ^a   Jayakumar, R ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY;

ACTIVE TARGETING; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; DRUG-DELIVERY RESEARCH; NANO-ENCAPSULATION; NANOMEDICINES; SURGICAL RESECTION; TOXIC SIDE EFFECTS;

DISEASES;

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CURCUMIN; DACTOLISIB; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ISOCOMBRETASTATIN A 4; NANOPARTICLE; PACLITAXEL; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; COLON CANCER; COLORECTAL CARCINOMA; DRUG DELIVERY SYSTEM; HUMAN; NANOENCAPSULATION; NANOMEDICINE; PRIORITY JOURNAL; SUICIDE GENE; SUICIDE GENE E; SUICIDE GENE THERAPY; COLONIC NEOPLASMS;

COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE;

EID: 84952876493     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1353     Document Type: Article

References (77)

1. Mateka JJL, Haniff MM, Bainey RS, Iliou CB. Interesting trends in incidence and mortality rates of colorectal cancer in the United States of America. J Gastrointest Dig Syst 2013, S6:004. doi:10.4172/2161-069X.S6-004.
2. Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from SEER data. PLoS One 2013, 8:e78709. doi:10.1371/journal.pone.0078709.
3. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993, 55:891-903.
4. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Atlanta, GA: American Cancer Society; 2011. Available at: http://www.cancer.org/research/cancerfactsfigures/colorectalcancerfactsfigures/colorectal-cancer-facts-figures-2011-2013-page.
5. American Cancer Society. Global Cancer Facts & Figures. 2nd ed. Atlanta, GA: American Cancer Society; 2011. Available at: http://globocan.iarc.fr/factsheets/cancers/colorectal.asp.
6. Hastings JB. Mass screening for colorectal cancer. Am J Surg 1974, 127:228-233.
7. Scholefield JH. Screening for colorectal cancer. Br Med Bull 2002, 64:75-80.
8. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010, 21:v70-v77. doi:10.1093/annonc/mdq168|v77.
9. Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, Lyerly HK, Diehl AM, Morse MA, Devi GR. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer 2012, 12:402.
10. Deng L, Ren Z, Jia O, Wu W, Shen H, Wang Y. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. BMC Cancer 2013, 13:363.
11. Subbarayan PR, Lee K, Ardalan B. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 in vitro re-sensitizing cells to 5-FU. Anticancer Res 2010, 30:1157-1162.
12. Wehler TC, Hamdi S, Maderer A, Graf C, Gockel I, Schmidtmann I, Hainz M, Berger MR, Theobald M, Galle PR, et al. Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft-no benefit of combination therapy. Int J Colorectal Dis 2013, 28:385-398.
13. Gonzalez-Vallinas M, Molina S, Vicente G, de la Cueva A, Vargas T, Santoyo S, Garcia-Risco MR, Fornari T, Reglero G, de Molina AR. Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol Res 2013, 72:61-68.
14. de laCueva A, de Molina AR, lvarez-Ayerza NA, Ramos MA, Cebrian A, Del Pulgar TG, Lacal JC. Combined 5-FU and ChoKa inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One 2013, 8:e64961. doi:10.1371/journal.pone.0064961.
15. Mehdi SM, Ali M, Cora L, Franziska B, Paviz S, Ajay G. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. PLoS One 2013, 8:e57218.
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
17. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008, 60:1650-1662.
18. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake. Eur J Pharm Biopharm 2000, 50:147-160.
19. Pinto RC, Neufeld RJ, Ribeiro AJ, Veiga A. Nanoencapsulation I methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
20. Wim HDJ, Paul JB. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008, 3:133-149.
21. Nazila K, Zeyu X, Pedro MV, Aleksandar FRM, Omid CF. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41:2971-3010.
22. Nishikant CS, Nisha JK, Prashant DA. Nanoparticles: advances in drug delivery systems. Res J Pharm Biol Chem Sci 2012, 3:922-929.
23. Jack HCM, Santosh A, Liangfang Z. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010, 1:323-334.
24. Giuseppe C, Silke H, Umile GS, Ortensia IP, Nevio P, Francesca I. Carbon nanotubes hybrid hydrogels in drug delivery: a perspective review. BioMed Res Int 2014, 17:825017.
25. Honary S, Ebrahimi PHR. Optimization of size and encapsulation efficiency of 5-FU loaded chitosan nanoparticles by response surface methodology. Curr Drug Deliv 2013, 10:742-752.
26. Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR, Farokzhad OC. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008, 8:1063-1070.
27. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761-769.
28. Hu CM, Kaushal S, Tran Cao HS, Aryal S, Sartor M, Esener S, Bouvet M, Zhang L. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm 2010, 7:914-920.
29. Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab 2009, 10:836-841.
30. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 2012, 83:1104-1111.
31. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60:1615-1626.
32. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems. J Pharm Sci 2007, 96:473-483.
33. Wu H, Zhu L, Torchilin VP. pH-sensitive poly (histidine)-PEG/DSPE-PEG-co-polymer micelles for cytosolic drug delivery. Biomaterials 2013, 34:1213-1222.
34. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56:1649-1659.
35. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
36. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
37. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
38. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. NK105, a paclitaxel-incorporating micelle nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005, 92:1240-1246.
39. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
40. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
41. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
42. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
43. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
44. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
45. Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv 2012, 2012:Article ID 915375, 17 pages.
46. Ratul KD, Naresh K, Utpal B. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 2010, 6:153-160.
47. Abhishek S, Utpal B, Naresh K, Pranab G. Synthesis of novel biodegradable and self-assembling methoxy poly (ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 2008, 4:1752-1761.
48. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007, 5:1-18.
49. Rejinold NS, Sreerekha PR, Chennazhi KP, Nair SV, Jayakumar R. Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly (N-isopropylacrylamide) nanocarrier for curcumin drug delivery. Int J Biol Macromol 2011, 49:161-172.
50. Santos IS, Ponte BM, Boonme P, Silva AM, Souto EB. Nanoencapsulation of polyphenols for protective effect against colon-rectal cancer. Biotechnol Adv 2013, 31:514-523.
51. Nair HB, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, Aggarwal BB. Delivery of anti-inflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol 2010, 80:1833-1843.
52. Sanna V, Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas 2012, 73:27-32. doi:10.1016/j.maturitas.2012.01.016.
53. Liechty WB, Peppas NA. Expert opinion: responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm 2012, 80:241-246.
54. Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: intelligent tools for intracellular targeting. Eur J Pharm Biopharm 2008, 68:112-128.
55. Mudshinge SR, Deore AB, Patil S, Bhalgat CM. Nanoparticles: emerging carriers for drug delivery. Saudi Pharma J 2011, 19:129-141.
56. Cho YS, Yoon TJ, Jang ES, Hong KS, Lee SY, Kim OR, Park C, Kim YJ, Yi GC, Chang K. Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. Cancer Lett 2010, 299:63-71.
57. Maya S, Sarmento B, Lakshmanan VK, Menon D, Jayakumar R. Actively targeted cetuximab conjugated γ-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells. J Biomed Nanotechnol 2014, 10:1416-1428.
58. Maya S, Kumar LG, Sarmento B, Rejinold NS, Menon D, Nair SV, Jayakumar R. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR over expressing cancer cells. Carbohydr Polym 2013, 93:661-669.
59. Sharma M, Malik R, Verma A, Dwivedi P, Banoth GS, Pandey N, Sarkar J, Mishra PR, Dwivedi AK. Folic acid conjugated guar gum nanoparticles for targeting methotrexate to colon cancer. J Biomed Nanotechnol 2013, 9:96-106.
60. Low K, Wacker M, Wagner S, Langer K, Briesen HV. Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. Nanomedicine 2011, 7:454-463.
61. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated super paramagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006, 78A:550-557.
62. Yang SJ, Lin FH, Tsai KC, Wei MF, Tsai HM, Wong JM, Shieh MJ. Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells. Bioconjug Chem 2010, 21:679-689.
63. Maksimenko A, Alami M, Zouhiri F, Brion JD, Pruvost A, Mougin J, Hamze A, Boissenot T, Provot O, Desmaele D, et al. Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS Nano 2014, 8:2018-2032.
64. Guo XY, Wang P, Du QG, Han S, Zhu SM, Lv YF, Liu GS, Hao ZM. Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers. Drug Res 2015, 65:199-204. doi:10.1055/s-0034-1375665.
65. Chen J, Shao R, Li L, Zhu ZP, Gu W. Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. Int J Nanomedicine 2014, 9:3403-3411.
66. Chen J, Huang XF, Qiao L, Katsifis A. Insulin caused drug resistance to oxaliplatin in colon cancer cell HT29. J Gastrointest Oncol 2011, 2:27-33.
67. Chen J, Katsifis A, Hu C, Huang XF. Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/ Akt pathway. Curr Drug Discov Technol 2011, 8:119-125.
68. Anitha A, Maya S, Chennazhi KP, Lakshmanan V-K, Jayakumar R. In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N, O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. Eur J Pharm Biopharm 2014, 88:238-251.
69. Anitha A, Deepa N, Chennazhi KP, Lakshmanan VK, Jayakumar R. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. Biochim Biophys Acta 2014, 1840:2730-2743.
70. Raul O, Jose P, Consolacion M, Jose LA, Ruiz MA, Pablo JA, Octavio C, Raquel L, Ana S, Antonia A. 5-Fluorouracil-loaded poly(ε{lunate}-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer. Int J Nanomedicine 2012, 7:95-107.
71. Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, Pashaei-Asl R, Omidi Y. Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM denderimers inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer Prev 2012, 13:4751-4756.
72. Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco MR, Eandi M, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004, 58:673-680.
73. Takakura Y, Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit Rev Oncol Hematol 1995, 18:207-231.
74. Kratz F, Beyer U, Schutte MT. Drug-polymer conjugates containing acid cleavable bonds. Crit Rev Ther Drug Carrier Syst 1999, 16:245-288.
75. Liu L, Xu K, Wang H, Tan PK, Fan W, Venkatraman SS, Li L, Yang Yi-Y. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009, 4:457-463.
76. Alexis F, Eric MP, Langer R, Omid CF. Nanoparticle technologies for cancer therapy. In: Schafer-Korting M, ed. Drug Delivery, Handbook of Experimental Pharmacology, vol. 197. Berlin Heidelberg: Springer-Verlag; 2010, 55-86.
77. Greco F, Vicent MJ. Polymer-drug conjugates: current status and future trends. Front Biosci 2008, 13:2744-2756.